Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01711879 · ClinicalTrials.gov registry record · NA
Use of Intravitreal Aflibercept Injection for Neovascular Glaucoma
A NA study, sponsored by University of Colorado, Denver.
- Completed
- Registry status
- NA
- Development phase
- 7
- Enrollment target
NCT01711879 is a NA study that has completed, run by University of Colorado, Denver. The registered enrollment target is 7 participants.
The verdict
NCT01711879, a NA study, has completed, sponsored by University of Colorado, Denver.
- COMPLETED
- Registry status
- NA
- Development phase
- 7 participants
- Enrollment target
Study Summary
This 52 week study will assess the use of intravitreal aflibercept injections in patients with neovascular glaucoma (NVG) compared to standard of care panretinal photocoagulation. The investigators hypothesize that the neovascularization of the iris and angle present in neovascular glaucoma will resolve more quickly in eye treated with intravitreal aflibercept injection alone and result in increased comfort and preservation of visual field as compared to current standard of care utilizing pan-retinal photocoagulation. The advantages to intravitreal aflibercept injection use could include resolution of NVI/NVA (neovascularization of the iris/neovascularization of the angle) leading to quicker pain relief and quicker lowering of IOP (intraocular pressure).
Interventions
- DRUG Aflibercept
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2013-01 |
| Est. Completion | 2015-10 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01711879
The ClinicalTrials.gov registry entry for NCT01711879 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Colorado, Denver, which has 1,283 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Aflibercept is the first listed.
NCT01711879 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01711879 about?
NCT01711879 is a clinical study titled "Use of Intravitreal Aflibercept Injection for Neovascular Glaucoma". This 52 week study will assess the use of intravitreal aflibercept injections in patients with neovascular glaucoma (NVG) compared to standard of care panretinal photocoagulation. The investigators hypothesize that the neovascularization of the iris and angle present in neovascular glaucoma will re...
What is the current status of trial NCT01711879?
This trial is currently completed. It is a NA study. The enrollment target is 7 participants. The study started on 2013-01. Estimated completion is 2015-10.
What interventions are being tested in trial NCT01711879?
The interventions under investigation include: Aflibercept (DRUG).
Who is sponsoring clinical trial NCT01711879?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.